AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$56.86
neg -3.41
-5.66%
Today's Range: 56.65 - 59.48 | ABBV Avg Daily Volume: 9,806,900
Last Update: 03/05/15 - 4:02 PM EST
Volume: 47,036,336
YTD Performance: -7.90%
Open: $57.21
Previous Close: $60.27
52 Week Range: $45.50 - $70.76
Oustanding Shares: 1,593,886,909
Market Cap: 95,027,537,515
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 8 6
Moderate Buy 0 0 0 1
Hold 4 4 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.67 1.73 1.55 1.65
Latest Dividend: 0.51
Latest Dividend Yield: 3.42%
Dividend Ex-Date: 04/13/15
Price Earnings Ratio: 54.20
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
54.20 54.10 27.80
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-13.37% 16.83% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
EBITDA 4.95B
Revenue 19.96B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.84 $1.08 $4.41 $5.09
Number of Analysts 6 6 8 8
High Estimate $0.86 $1.10 $4.45 $5.38
Low Estimate $0.83 $1.03 $4.39 $4.77
Prior Year $0.72 $0.82 $3.32 $4.41
Growth Rate (Year over Year) 16.90% 31.10% 32.87% 15.42%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Stocks that stabilized yesterday were terrific today.
Kroger is a good example of execution.

Recommended Reading, Part Deux Real Money Pro($)

In Jim "El Capitan" Cramer's "Return of the Cult Stocks," he talks about comebacks in Tesla (TSLA), Facebook (FB), Netflix (NFLX), Amazon (AMZN) and others -- even Ali Blah Blah (BABA) and GoPro (GPRO) have had a rally, albeit from depressed levels. 
The cult of the buyer stays devoted to Tesla, Netflix, Amazon and more.
And four other things you need to know now.
This vaccine maker is now closer to several important milestones.
Because now is not the time to get complacent in this market.

From the Street of Dreams Real Money Pro($)

Deutsche Bank reiterates its Buy recommendation on Gilead (GILD) (price target $125) based on the company's exclusive agreement with AbbVie (ABBV) for its HCV drug.
Watch this leadership group that's been lagging.
They're in the tech, pharma and biotechnology sectors.

Columnist Conversations

Weyerhaeuser (WY) is seeing further weakness after penetrating the channel support I noted yesterday. It looks...
Blow off highs tend to take place on significant news days. In recent years, the monthly employment report ha...
Market trying to hold on to minor gains as we head into the close. Equities have been in a pretty narrow trad...
Shares near $4 and a buyer paid 50c for nearly 1500 Sep 5 calls to open a new position 25% above spot. Earning...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.